Alpha fetoprotein targeted T-cell therapy - Adaptimmune

Drug Profile

Alpha fetoprotein targeted T-cell therapy - Adaptimmune

Alternative Names: AFP SPEAR T-cell therapy; AFP TCR - Adaptimmune; AFPᶜ³³²T cell therapy - Adaptimmune; Autologous genetically modified AFPᶜ³³² T-cells - Adaptimmune

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Adaptimmune
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatocellular carcinoma

Most Recent Events

  • 01 May 2017 Phase-I clinical trials in Hepatocellular carcinoma (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in USA (IV) (NCT03132792)
  • 13 Mar 2017 Adaptimmune Therapeutics files for patent protection with patent co-operation treaty for AFP SPEAR T-cell therapy before March 2017
  • 13 Mar 2017 Adaptimmune Therapeutics has patents pending for AFP SPEAR T-cell therapy in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top